IDL Diagnostics AB (publ)
The answer first
Does IDL Diagnostics beat the market?
No, IDL Diagnostics has not beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 86% of Nordic stocks
- Quality95
- Value98
- Trend13
No. 18 of 195 in healthcare
Expectations in the price
Very high expectations
For the share to return about 9% a year from today's price, the cash IDL Diagnostics keeps must grow more than 60% a year for 10 years.
Max for seven days
Follow IDL Diagnostics with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about IDL Diagnostics
Your first answer is free, no account needed.
Do you own IDL Diagnostics, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with IDL Diagnostics and a few more. Free, no card.
Super Stock+44.6%In short
- IDL Diagnostics has fallen 28.1% over the past year, including dividends.
- Overall, IDL Diagnostics ranks better than 86% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 95.1%. The price is 98.1% below its peak now.
What do analysts think of IDL Diagnostics?
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 86% of Nordic stocks.
No. 18 of 195 in healthcare
High A solid company: it earns well on its money and has healthy finances.
No. 19 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity0.09
- Asset turnoverSales divided by everything the company owns0.34
- Return on equityProfit divided by equity+11.3%
- Cash conversionOperating cash flow divided by profit0.04
The ranking is built on equity ratio, ROA and how steadily profit grows.
High Low price: you pay little for what the company earns and owns.
No. 4 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50
- P/BPrice divided by equity0.5
- P/SPrice divided by sales1.2
- P/EPrice divided by earnings4.2
- P/CFPrice divided by operating cash flow93.1
The ranking is built on P/E, P/B and P/S.
Low Headwind in the share price: it has done worse than most over the last year.
No. 151 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months−25.8%
- 6 months−41.6%
- 9 months−17.3%
- 12 months−28.1%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
The funds that own IDL Diagnostics
One fund we follow owns IDL Diagnostics. The share is how much of the fund the stock makes up.
- Sweden1
From the funds' latest known holdings.
About IDL Diagnostics
IDL Diagnostics AB (publ) is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 25 employees.
IDL Diagnostics AB (publ), a vitro diagnostics company, manufactures and sells IVD tests for oncological and bacterial diseases in Sweden. It offers UBC Rapid, a point-of-care test for diagnosis and monitoring of bladder cancer; AroCell TK 210 ELISA, a biomarker for tumor cells; and TUBEX TF, a vitro diagnostic test for detection of acute typhoid fever. Its vitro diagnostic biomarkers are used in breast, bladder, and prostate cancer therapies. The company was formerly known as AroCell AB (publ) and changed its name to IDL Diagnostics AB (publ) in May 2025. IDL Diagnostics AB (publ) was incorporated in 2000 and is based in Stockholm, Sweden.


See the full analysis of IDL Diagnostics.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card